Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 517-528

  Jacquemart, Isabelle C ^a,b   Springs, Alison E B ^a,b   Chen, Wen Y ^a,b  

^a CLEMSON UNIVERSITY   (United States)

^b GREENVILLE HOSPITAL SYSTEM   (United States)

Author keywords

HER2 neu mammary tumorigenesis; MMTV neu transgenic mice; Rassf3; Tumor suppressor gene

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 3; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER INCIDENCE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR RESISTANCE; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE; UPREGULATION;

ANIMALS; APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CELL SURVIVAL; DNA PRIMERS; FEMALE; GENES, ERBB-2; GENES, TUMOR SUPPRESSOR; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MONOMERIC GTP-BINDING PROTEINS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 64549157275     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000177     Document Type: Article

References (28)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
3. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD and Muller WJ: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578-10582, 1992.
4. Lodish H BD, Berk A, Zipursky SL, Matsudaira P: Molecular Cell Biology. W.H. Freeman and Co., New York, 2001.
5. Bazley LA and Gullick WJ: The epidermal growth factor receptor family. Endocr Relat Cancer 12 (Suppl 1): 17-27, 2005.
6. Clark GJ and Der CJ: Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 35: 133-144, 1995.
7. von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE and Boss GR: Ras activation in human breast cancer. Breast Cancer Res Treat 62: 51-62, 2000.
8. Rodriguez-Viciana P, Sabatier C and McCormick F: Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 24: 4943-4954, 2004.
9. Lowy DR, Johnson MR, DeClue JE, et al: Cell transformation by ras and regulation of its protein product. Ciba Found Symp 176: 67-80, 1993.
10. Chen CY and Faller DV: Direction of p21ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene 11: 1487-1498, 1995.
11. Chen CY, Liou J, Forman LW and Faller DV: Differential regulation of discrete apoptotic pathways by Ras. J Biol Chem 273: 16700-16709, 1998.
12. Khokhlatchev A, Rabizadeh S, Xavier R, et al: Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 12: 253-265, 2002.
13. Shao J, Sheng H, DuBois RN and Beauchamp RD: Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem 275: 22916-22924, 2000.
14. Cox AD and Der CJ: The dark side of Ras: regulation of apoptosis. Oncogene 22: 8999-9006, 2003.
15. Agathanggelou A, Cooper WN and Latif F: Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 65: 3497-3508, 2005.
16. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F and Clark GJ: RASSF4/ AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res 64: 8688-8693, 2004.
17. Hesson L, Dallol A, Minna JD, Maher ER and Latif F: NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 22: 947-954, 2003.
18. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ and Clark GJ: RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 278: 28045-28051, 2003.
19. Wagner TE, Hoppe PC, Jollick JD, Scholl DR, Hodinka RL and Gault JB: Microinjection of a rabbit beta-globin gene into zygotes and its subsequent expression in adult mice and their offspring. Proc Natl Acad Sci USA 78: 6376-6380, 1981.
20. Raccurt M, Tam SP, Lau P, et al: Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br J Cancer 89: 524-532, 2003.
21. Tommasi S, Dammann R, Jin SG, Zhang Xf XF, Avruch J and Pfeifer GP: RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 21: 2713-2720, 2002.
22. Goel A and Janknecht R: Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. J Biol Chem 279: 14909-14916, 2004.
23. Campbell MJ, Wollish WS, Lobo M and Esserman LJ: Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse. In Vitro Cell Dev Biol Anim 38: 326-333, 2002.
24. Oft M, Heider KH and Beug H: TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8: 1243-1252, 1998.
25. Gonzalez-Palacios F, Sancho M, Martinez JC and Bellas C: Microvessel density, p53 overexpression, and apoptosis in invasive breast carcinoma. Mol Pathol 50: 304-309, 1997.
26. Rowland BD and Peeper DS: KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer 6: 11-23, 2006.
27. Yan J, Roy S, Apolloni A, Lane A and Hancock JF: Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 273: 24052-24056, 1998.
28. Tommasi S, Dammann R, Zhang Z, et al: Tumor susceptibility of Rassf1a knockout mice. Cancer Res 65: 92-98, 2005.